Perspective's VMT-α-NET Shows 75% 18-Month PFS in SSTR2+ GEP-NETs; End-of-Phase 2 Targeted 1Q 2027
CATX is trading near its 52-week low of $0.781 (4.9% above the low).
Summary
Perspective presented incremental Phase 1/2a data showing 75% 18-month PFS and 37-47% response rates in SSTR2+ GEP-NET patients, with a clean safety profile, and said it is targeting an End-of-Phase 2 FDA meeting in 1Q 2027 ahead of a 2027 Phase 3 start.
Key Events · Product Development and Regulatory · CATX
-
NANETS Data Show Durable PFS
Across Cohorts 1-3, the 57 GEP-NET patients with SSTR2 expression in all target lesions showed PFS of 91% at 6 months, 78% at 12 months and 75% at 18 months.
-
Response Rates in SSTR2+ Subgroup
Objective response rate was 37% (14 of 38) in Cohort 2 and 47% (8 of 17) in Cohort 3; disease control was 92% and 100%, respectively.
-
Clean Safety Across 68 Patients
No dose-limiting toxicities, no Grade 4 or 5 treatment-emergent events and no treatment-related discontinuations; Grade 3 events occurred in 20 of 68 patients (29%).
-
End-of-Phase 2 Meeting Targeted 1Q 2027
The company is incorporating the SSTR2-enriched population into FDA discussions and targets an End-of-Phase 2 meeting in the first quarter of 2027, with Phase 3 initiation expected in 2027.
Analysis · CATX · Life Sciences
The NANETS dataset offers the clearest efficacy read yet for Perspective's lead radiopharmaceutical. Among the 57 GEP-NET patients whose target lesions all express SSTR2, 75% remained progression-free at 18 months, versus roughly 65% at 18 months for the approved lutetium-177 benchmark cited in its U.S. label; objective responses occurred in 37% (Cohort 2) and 47% (Cohort 3) of that subgroup. Safety held up, with no dose-limiting toxicities, no Grade 4 or 5 treatment-emergent events and no treatment-related discontinuations across 68 treated patients. Perspective now says it is folding this SSTR2-enriched population into regulator discussions and targeting an End-of-Phase 2 meeting in the first quarter of 2027, with Phase 3 initiation expected in 2027. That makes the next hard checkpoint a regulatory one, and the stock — trading near its 52-week low — is priced for execution risk on a program that still needs cash to reach a registrational trial.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CATX was trading at $0.82 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $90M. The 52-week trading range was $0.78 to $6.16. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.